NMR Innovation Offers Insights into Protein Interaction
|
By LabMedica International staff writers Posted on 17 Jul 2013 |

Image: A permissive captor A computer rendering depicts a GroEL protein hunting down an Aβ protein. Four complementary styles of nuclear magnetic resonance spectroscopy contributed to an understanding of the protein-to-protein interaction (Photo courtesy of Fawzi lab at Brown University).
By taking a novel approach to nuclear magnetic resonance spectroscopy--a fusion of four techniques--scientists have been able to resolve a key interaction between two proteins that could never be seen before.
The findings were published the week of June 24, 2013, in the Proceedings of the National Academy of Sciences of the United States of America (PNAS). The interaction the researchers became the first ones to describe is nearly universal across all of life. A protein unit called a chaperone takes hold of a disordered smaller protein to help it find its correct folded conformation. The scientists, in this instance, initiated test-tube experiments where they hoped to visualize the capsule-shaped bacterial chaperone GroEL capture a disordered amyloid beta (A-beta) protein, a molecule that in humans is central in Alzheimer's disease.
The two proteins are well researched, but the motions they go through when they first meet, i.e., when the open GroEL capsule captures its target, have been invisible to scientists. Electron microscopy and X-ray crystallography are only good for taking snapshots of easily frozen moments in time. NMR is capable of sensing the interactions and kinetics of protein interactions as they occur, but in some cases, any single technique can provide only clues into what is actually going on.
Brown University (Providence, RI, USA) biologist Dr. Nicolas Fawzi, who was a post-doc in the group of Marius Clore’s at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) within the US National Institutes of Health (NIH; Bethesda, MD, USA), worked with coauthors and NIDDK researchers Drs. David Libich, Jinfa Yang, and Marius Clore assembling the interactions of the proteins by combining four different NMR techniques. They determined what each one could inform them about the interaction and built the case presented in PNAS.
“None of the four techniques alone gave us sufficient information,” said Dr. Fawzi, now an assistant professor in Brown’s department of molecular pharmacology, physiology, and biotechnology. “Only by using them all together would we be able to figure out the structure and motions of A-beta; when it was bound to GroEL. By having four indirect measurements together, that was able to give us a complete picture.”
The NMR techniques they used were lifetime line broadening, Carr-Purcell-Meinboom-Gill (CPMG) relaxation dispersion spectroscopy, and exchange-induced chemical shifts. “The fourth technique we employed was dark-state exchange saturation transfer [DEST] spectroscopy, which we had developed in my lab at the NIH in 2011,” said Dr. Clore, also the article’s corresponding author. “We were able to more effectively conduct our research by using that tool to corroborate and extend the information afforded by the other three measurements.”
The elusive process debated among molecular biologists was about what the GroEL chaperone requires of its captives at the moment they engage. Does it force them into a specific conformation? Does it hold on tightly while it closes its capsule lid around the smaller protein, or does the captive stay in motion at all?
What the investigators observed is that the GroEL is a permissive captor. It bound A-beta; at just two hydrophobic sites, leaving the smaller protein to otherwise swing in a range of conformations. It also did not keep it bound the entire time, letting it instead detach and re-bind. Basically, A-beta would jump off and on within GroEL’s binding cavity.
“By using these four techniques together we were able to extract information about the structure of the protein while it binds as well as how fast it comes on and off and what it's doing at each position,” Dr. Fawzi said. “Instead of forming more particular structure upon binding it appears to retain great conformational heterogeneity.”
The lifetime line-broadening technique, for example, informed them that the A-beta; was interacting with something big (GroEL), while the CPMG and chemical shift observations combined to show the length of time A-beta; spent on GroEL before unbinding, as well as the structural characteristics of A-beta; when it was bound to GroEL. DEST provided data that could validate much of the story of the other techniques.
Dr. Fawzi noted that GroEL’s relaxed strategy could be a matter of being able to bind many different proteins in disordered conformations, but also of saving energy. Forcing proteins into a specific conformation just to make and sustain the initial capture would require more energy than it is worth. Eventually, in moments after those the team resolved in this study, GroEL closes its lid and encapsulates its target proteins fully, according to Dr. Fawzi said. Thatis when it capitalizes on in compelling them to fold in the correct manner.
For molecular and structural biologists, the newly proven combination of NMR techniques could create a number of other cold cases of elusive interactions. “We can now look at how these big machines can do their job while they are working,” Dr. Fawzi said. “This is not just limited to this GroEL machine.”
Related Links:
Brown University
The findings were published the week of June 24, 2013, in the Proceedings of the National Academy of Sciences of the United States of America (PNAS). The interaction the researchers became the first ones to describe is nearly universal across all of life. A protein unit called a chaperone takes hold of a disordered smaller protein to help it find its correct folded conformation. The scientists, in this instance, initiated test-tube experiments where they hoped to visualize the capsule-shaped bacterial chaperone GroEL capture a disordered amyloid beta (A-beta) protein, a molecule that in humans is central in Alzheimer's disease.
The two proteins are well researched, but the motions they go through when they first meet, i.e., when the open GroEL capsule captures its target, have been invisible to scientists. Electron microscopy and X-ray crystallography are only good for taking snapshots of easily frozen moments in time. NMR is capable of sensing the interactions and kinetics of protein interactions as they occur, but in some cases, any single technique can provide only clues into what is actually going on.
Brown University (Providence, RI, USA) biologist Dr. Nicolas Fawzi, who was a post-doc in the group of Marius Clore’s at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) within the US National Institutes of Health (NIH; Bethesda, MD, USA), worked with coauthors and NIDDK researchers Drs. David Libich, Jinfa Yang, and Marius Clore assembling the interactions of the proteins by combining four different NMR techniques. They determined what each one could inform them about the interaction and built the case presented in PNAS.
“None of the four techniques alone gave us sufficient information,” said Dr. Fawzi, now an assistant professor in Brown’s department of molecular pharmacology, physiology, and biotechnology. “Only by using them all together would we be able to figure out the structure and motions of A-beta; when it was bound to GroEL. By having four indirect measurements together, that was able to give us a complete picture.”
The NMR techniques they used were lifetime line broadening, Carr-Purcell-Meinboom-Gill (CPMG) relaxation dispersion spectroscopy, and exchange-induced chemical shifts. “The fourth technique we employed was dark-state exchange saturation transfer [DEST] spectroscopy, which we had developed in my lab at the NIH in 2011,” said Dr. Clore, also the article’s corresponding author. “We were able to more effectively conduct our research by using that tool to corroborate and extend the information afforded by the other three measurements.”
The elusive process debated among molecular biologists was about what the GroEL chaperone requires of its captives at the moment they engage. Does it force them into a specific conformation? Does it hold on tightly while it closes its capsule lid around the smaller protein, or does the captive stay in motion at all?
What the investigators observed is that the GroEL is a permissive captor. It bound A-beta; at just two hydrophobic sites, leaving the smaller protein to otherwise swing in a range of conformations. It also did not keep it bound the entire time, letting it instead detach and re-bind. Basically, A-beta would jump off and on within GroEL’s binding cavity.
“By using these four techniques together we were able to extract information about the structure of the protein while it binds as well as how fast it comes on and off and what it's doing at each position,” Dr. Fawzi said. “Instead of forming more particular structure upon binding it appears to retain great conformational heterogeneity.”
The lifetime line-broadening technique, for example, informed them that the A-beta; was interacting with something big (GroEL), while the CPMG and chemical shift observations combined to show the length of time A-beta; spent on GroEL before unbinding, as well as the structural characteristics of A-beta; when it was bound to GroEL. DEST provided data that could validate much of the story of the other techniques.
Dr. Fawzi noted that GroEL’s relaxed strategy could be a matter of being able to bind many different proteins in disordered conformations, but also of saving energy. Forcing proteins into a specific conformation just to make and sustain the initial capture would require more energy than it is worth. Eventually, in moments after those the team resolved in this study, GroEL closes its lid and encapsulates its target proteins fully, according to Dr. Fawzi said. Thatis when it capitalizes on in compelling them to fold in the correct manner.
For molecular and structural biologists, the newly proven combination of NMR techniques could create a number of other cold cases of elusive interactions. “We can now look at how these big machines can do their job while they are working,” Dr. Fawzi said. “This is not just limited to this GroEL machine.”
Related Links:
Brown University
Latest BioResearch News
- Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
- Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
- New Method Simplifies Preparation of Tumor Genomic DNA Libraries
- New Tool Developed for Diagnosis of Chronic HBV Infection
- Panel of Genetic Loci Accurately Predicts Risk of Developing Gout
- Disrupted TGFB Signaling Linked to Increased Cancer-Related Bacteria
- Gene Fusion Protein Proposed as Prostate Cancer Biomarker
- NIV Test to Diagnose and Monitor Vascular Complications in Diabetes
- Semen Exosome MicroRNA Proves Biomarker for Prostate Cancer
- Genetic Loci Link Plasma Lipid Levels to CVD Risk
- Newly Identified Gene Network Aids in Early Diagnosis of Autism Spectrum Disorder
- Link Confirmed between Living in Poverty and Developing Diseases
- Genomic Study Identifies Kidney Disease Loci in Type I Diabetes Patients
- Liquid Biopsy More Effective for Analyzing Tumor Drug Resistance Mutations
- New Liquid Biopsy Assay Reveals Host-Pathogen Interactions
- Method Developed for Enriching Trophoblast Population in Samples
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more







